Atrasentan Tied to Lower Risk for Kidney Events in T2DM With CKD
Reduced risk seen for primary composite renal end point event; more frequent fluid retention, anemia reported
Reduced risk seen for primary composite renal end point event; more frequent fluid retention, anemia reported
Nondihydropyridine calcium channel blockers (non-DHP CCBs) appear to reduce proteinuria in patients with diabetic kidney disease
In a study of patients with type 2 diabetes and chronic kidney disease, canagliflozin, an SGLT2 inhibitor, decreased the risk of end-stage renal disease by 32% compared with placebo.
New findings suggest that diabetic patients with advanced chronic kidney disease may need different glucose control strategies depending on whether or not they are transitioning to dialysis.
SGLT2i reduced the risks for progression of renal disease by 45% and heart failure hospitalization by 31% in patients with type 2 diabetes.
Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.
Strict BP control, fenofibrate use may increase long-term risk for adverse kidney events in T2DM patients
Additional focus on lifestyle management, self-management education and support emphasized
New study shows metformin is not associated with an increased risk of acidosis in patients with type 2 diabetes and an eGFR of 30 to 60 mL/min/1.73 m2.
Relative risk of end-stage renal disease was 0.13 in those diagnosed in 1995-2011 versus 1965-1979.